Institute achieves top international ranking

Institute achieves top international ranking

Illuminate newsletter index page, September 2019
September 2019

The Walter and Eliza Hall Institute
The Nature Index placed the Walter and Eliza Hall Institute
as the top-ranked Australian medical research institute.

The Walter and Eliza Hall Institute was the top-ranked Australian medical research institute in the 2019 Nature Index. The index ranks organisations according to their contribution to publications in leading biomedical research journals, a measure of scientific excellence.

Measuring success

Some of the 79 publications that influenced the Institute’s position include developing first-in-class anti-cancer agents, revealing how genes guide healthy development, uncovering immune clues that could help to prevent inflammatory diseases and revealing how malaria evades host defences.

Institute director Professor Doug Hilton AO said the ranking was a reflection of the Institute’s international standing as a biomedical research institute.

“The Institute is known in Australia and around the word for its longstanding scientific excellence. I am proud to see this recognised in our position in the Nature Index, alongside other world-class research organisations internationally,” Professor Hilton said.

Professor Hilton said while the ranking was significant, it was just one way in which the Institute measured excellence.

“We place a high value on collaboration, translation, community engagement and education as measurements of excellence. Our success can also be seen in the impact of our discoveries on the health of our community, and the calibre and contribution of all our staff, students and alumni.”

Super Content: 
Two researchers smiling at the camera

The Nature Index placed the Institute as the top-ranked Australian medical research institute, and 19th amongst not-for-profit/non-governmental organisations worldwide.

Researchers and Health Minister with robotic equipment

The Australian Government has committed to $25 million in funding to enhance drug discovery capabilities at the Institute’s Drug Discovery Centre.